Eichenfield LF, Ahluwalia J, Waldman A, et al. Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017;139(4S):S49–57.

Article  Google Scholar 

Smith P, Yao W, Shepard S, et al. Developing a JAK inhibitor for targeted local delivery: ruxolitinib cream. Pharmaceutics. 2021;13(7):1044.

Article  CAS  Google Scholar 

Nakashima C, Yanagihara S, Otsuka A. Innovation in the treatment of atopic dermatitis: emerging topical and oral Janus kinase inhibitors. Allergol Int. 2021;71(1):40–6.

Article  Google Scholar 

O’Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–28.

Article  CAS  Google Scholar 

Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342.

Article  CAS  Google Scholar 

Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–32.

Article  Google Scholar 

Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–82.

Article  CAS  Google Scholar 

Muller SM, Tomaschett D, Euler S, et al. Topical corticosteroid concerns in dermatological outpatients: a cross-sectional and interventional study. Dermatology. 2016;232(4):444–52.

Article  Google Scholar 

Incyte Corporation. OPZELURA™ (ruxolitinib) cream, for topical use: US prescribing information. 2022. https://dailymed.nlm.nih.gov/. Accessed 28 Nov 2022.

Fridman JS, Scherle PA, Collins R, et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol. 2011;131(9):1838–44.

Article  CAS  Google Scholar 

Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109–17.

Article  CAS  Google Scholar 

Scuron MD, Fay BL, Connell AJ, et al. Ruxolitinib cream has dual efficacy on pruritus and inflammation in experimental dermatitis. Front Immunol. 2020;11: 620098.

Article  CAS  Google Scholar 

Owens S, Liu H, Sun K, et al. Ruxolitinib cream significantly modulates inflammatory profiles of atopic dermatitis patients [abstract no. 998]. J Invest Dermatol. 2019;139(5 Suppl):S173.

Article  Google Scholar 

Owens S, Howell MD. Ruxolitinib cream suppresses Th2 inflammation in adult patients with atopic dermatitis [abstract no. 384]. J Allergy Clin Immunol. 2019;143(2 Suppl):AB128.

Article  Google Scholar 

Liu H, Gong X, Smith SH. Clinical serum biomarker profiling in TRuE-AD1 and TRuE-AD2 studies after 8 weeks of treatment with ruxolitinib cream [abstract no. LB991]. In: Society for Investigative Dermatology Annual Meeting. 2022.

Gong X, Chen X, Kuligowski ME, et al. Pharmacokinetics of ruxolitinib in patients with atopic dermatitis treated with ruxolitinib cream: data from phase II and III studies. Am J Clin Dermatol. 2021;22(4):555–66.

Article  Google Scholar 

Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863–72.

Article  CAS  Google Scholar 

Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020;145(2):572–82.

Article  CAS  Google Scholar 

Kim BS, Sun K, Papp K, et al. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. J Am Acad Dermatol. 2020;82(6):1305–13.

Article  CAS  Google Scholar 

Bissonnette R, Call RS, Raoof T, et al. A maximum-use trial of ruxolitinib cream in adolescents and adults with atopic dermatitis. Am J Clin Dermatol. 2022;23(3):355–64.

Article  Google Scholar 

Persaud I, Diamond S, Pan R, et al. Plasma pharmacokinetics and distribution of ruxolitinib into skin following oral and topical administration in minipigs. Int J Pharm. 2020;590: 119889.

Article  CAS  Google Scholar 

Papp K, Szepietowski JC, Kircik L, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies [abstract no. 511 plus poster]. Br J Dermatol. 2021;185(3):e134–5.

Google Scholar 

Eichenfield LF, Simpson E, Papp K, et al. Long-term safety and disease control of ruxolitinib cream among adolescents with atopic dermatitis: results from two phase 3 studies [abstract no. 49]. Pediatric Dermatol. 2021;38(5):1433.

Google Scholar 

Papp K, Szepietowski JC, Kircik L, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. J Am Acad Dermatol. 2022. https://doi.org/10.1016/j.jaad.2022.09.060.

Article  Google Scholar 

Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: pooled analysis of two phase III, randomized, double-blind studies [abstract no. 337 plus poster]. Br J Dermatol. 2021;184(3):e62–3.

Google Scholar 

Blauvelt A, Kircik L, Papp KA, et al. Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2022. https://doi.org/10.1111/jdv.18571.

Article  Google Scholar 

Papp K, Szepietowski JC, Kircik L, et al. Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by baseline patient demographics: pooled subgroup analysis from two randomized phase 3 studies [abstract no. 27496]. J Am Acad Dermatol. 2021;85(3 Suppl):AB149.

Article  Google Scholar 

Simpson E, Lee M, Brar KK, et al. Efficacy of ruxolitinib cream in adults and adolescents with atopic comorbidities [abstract no. 329]. J Invest Dermatol. 2021;141(5 Suppl):S58.

Article  Google Scholar 

Papp K, Szepietowski JC, Kircik L, et al. Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by baseline clinical characteristics: pooled subgroup analysis from two randomized phase 3 studies [abstract no. 27716]. J Am Acad Dermatol. 2021;85(3 Suppl):AB160.

Article  Google Scholar 

Simpson EL, Kircik L, Blauvelt A, et al. Effects of ruxolitinib cream in patients with atopic dermatitis with baseline body surface area ≥10% and Eczema Area and Severity Index score ≥16: pooled results from two phase 3 studies [abstract no. 27620]. J Am Acad Dermatol. 2021;85(3 Suppl):AB157.

Article  Google Scholar 

Simpson E, Bissonnette R, Kuligowski ME, et al. Effects of ruxolitinib cream in patients with atopic dermatitis with head and/or neck involvement [abstract no. 311]. J Invest Dermatol. 2021;141(5 Suppl):S55.

Article  Google Scholar 

Blauvelt A, Eichenfield LF, Kuligowski ME, et al. Efficacy of ruxolitinib cream among patients with atopic dermatitis based on previous medication history: pooled results from two phase 3 studies [abstract no. 27482]. J Am Acad Dermatol. 2021;85(3 Suppl):AB148.

Article  Google Scholar 

Simpson EL, Kircik L, Blauvelt A, et al. Efficacy of ruxolitinib cream in patients with atopic dermatitis who demonstrated partial responses: pooled analysis from two randomized phase 3 studies [abstract no. 24916]. J Am Acad Dermatol. 2021;85(3 Suppl):AB50.

Article  Google Scholar 

Blauvelt A, Eichenfield LF, Kuligowski ME, et al. Long-term safety and disease control with ruxolitinib cream in patients with atopic dermatitis based on previous medication history: pooled results from two phase III studies [abstract no. 515]. Br J Dermatol. 2021;185(3):e136–7.

Google Scholar 

Simpson EL, Kircik L, Blauvelt A, et al. Long-term safety and disease control with ruxolitinib cream in patients with more severe atopic dermatitis: pooled results from two phase III studies [abstract no. 513]. Br J Dermatol. 2021;185(3):e135–6.

Google Scholar 

Papp K, Szepietowski JC, Kircik L, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: pooled results from two phase 3 studies [abstract no. 94 plus poster]. Exp Dermatol. 2021;30(Suppl 2):43.

Google Scholar 

Blauvelt A, Szepietowski JC, Papp K, et al. Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: pooled analysis from two randomized phase 3 studies. J Am Acad Dermatol. 2022. https://doi.org/10.1016/j.jaad.2022.09.010.

Article  Google Scholar 

Bloudek L, Eichenfield LF, Silverberg JI, et al. Impact of ruxolitinib cream on work productivity and activity impairment and associated indirect costs in patients with atopic dermatitis: pooled results from two phase III studies. Am J Clin Dermatol. 2022. https://doi.org/10.1007/s40257-022-00734-8.

Article  Google Scholar 

US National Institutes of Health. ClinicalTrials.gov identifier NCT03745638. 2021. https://clinicaltrials.gov/. Accessed 28 Nov 2022.

US National Institutes of Health. ClinicalTrials.gov identifier NCT03745651. 2021. https://clinicaltrials.gov/. Accessed 28 Nov 2022.